Skip to main content
Terug
ALNY logo

Alnylam Pharmaceuticals, Inc.

Datakwaliteit: 100%
ALNY
NASDAQ Healthcare Biotechnology
€ 308,05
▲ € 1,39 (0,45%)
Marktkapitalisatie: 40,85B
Dagbereik
€ 299,69 € 308,91
52-Weeksbereik
€ 205,87 € 495,55
Volume
1.494.718
50D / 200D Gem.
€ 337,90 / € 392,53
Vorige Slotkoers
€ 306,66

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 130,2 0,3
P/B 51,8 2,9
ROE % 73,3 3,7
Net Margin % 8,5 3,8
Rev Growth 5Y % 44,8 10,0
D/E 1,6 0,2

Koersdoel Analisten

Hold
€ 460,50 +49.5%
Low: € 351,00 High: € 549,00
Forward K/W
45,1
Forward WPA
€ 6,80
WPA Groei (sch.)
+0,0%
Omzet Sch.
5,6 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 19,29
€ 16,99 – € 23,76
11 B 14
FY2029 € 16,25
€ 14,31 – € 20,01
10 B 14
FY2028 € 13,74
€ 9,81 – € 20,45
8,8 B 16

Belangrijkste Punten

Revenue grew 44,82% annually over 5 years — strong growth
ROE of 73,28% indicates high profitability
Generating 465,38M in free cash flow
P/E of 130,21 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 20,37%
Cash machine — converts 148,33% of earnings into free cash flow

Groei

Revenue Growth (5Y)
44,82%
Revenue (1Y)65,19%
Earnings (1Y)N/A
FCF Growth (3Y)233,09%

Kwaliteit

Return on Equity
73,28%
ROIC18,19%
Net Margin8,45%
Op. Margin13,51%

Veiligheid

Debt / Equity
1,62
Current Ratio2,76
Interest Coverage1,99

Waardering

P/E Ratio
130,21
P/B Ratio51,77
EV/EBITDA80,70
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 65,19% Revenue Growth (3Y) 42,53%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 44,82% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 3,71B Net Income (TTM) 313,75M
ROE 73,28% ROA 6,32%
Gross Margin 81,77% Operating Margin 13,51%
Net Margin 8,45% Free Cash Flow (TTM) 465,38M
ROIC 18,19% FCF Growth (3Y) 233,09%
Safety
Debt / Equity 1,62 Current Ratio 2,76
Interest Coverage 1,99 Dividend Yield 0,00%
Valuation
P/E Ratio 130,21 P/B Ratio 51,77
P/S Ratio 11,00 PEG Ratio -0,79
EV/EBITDA 80,70 Dividend Yield 0,00%
Market Cap 40,85B Enterprise Value 40,48B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3,71B 2,25B 1,83B 1,04B 844,29M
Net Income 313,75M -278,16M -440,24M -1,13B -852,82M
EPS (Diluted) 2,33 -2,18 -3,52 -9,30 -7,20
Gross Profit 3,04B 1,92B 1,52B 868,60M 704,14M
Operating Income 501,58M -176,89M -282,18M -785,07M -708,65M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 4,97B 4,24B 3,83B 3,55B 3,64B
Total Liabilities 4,18B 4,17B 4,05B 3,70B 3,06B
Shareholders' Equity 789,18M 67,09M -220,64M -158,22M 588,20M
Total Debt 1,28B 2,74B 1,31B 1,32B 997,59M
Cash & Equivalents 1,66B 966,43M 812,69M 866,39M 819,98M
Current Assets 4,05B 3,30B 2,98B 2,69B 2,81B
Current Liabilities 1,47B 1,19B 967,79M 767,92M 695,71M